Brett G.M. Hughes,
Alexander Guminski,
Samantha Bowyer,
Michael R. Migden,
Chrysalyne D. Schmults,
Nikhil I. Khushalani,
Anne Lynn S. Chang,
Jean-Jacques Grob,
Karl D. Lewis,
George Ansstas,
Fiona Day,
Rahul Ladwa,
Brian N. Stein,
Eva Muñoz Couselo,
Friedegund Meier,
Axel Hauschild,
Dirk Schadendorf,
Nicole Basset-Seguin,
Badri Modi,
Sophie Dalac-Rat,
Lara A. Dunn,
Lukas Flatz,
Laurent Mortier,
Sarah Guégan,
Lucie M. Heinzerling,
Janice M. Mehnert,
Sabiha Trabelsi,
Ainara Soria-Rivas,
Alexander J. Stratigos,
Claas Ulrich,
Deborah J. Wong,
Marie Beylot-Barry,
Paolo Bossi,
Cristina Bugés Sánchez,
Sunandana Chandra,
Caroline Robert,
Jeffery S. Russell,
Ann W. Silk,
Jocelyn Booth,
Suk-Young Yoo,
Frank Seebach,
Israel Lowy,
Matthew G. Fury,
Danny Rischin:
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
in Journal of the American Academy of Dermatology: JAAD,
volume 92,
(1),
pages: 68—77,
1097-6787 [en]